Eikon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-324.25	-243.81	-242
Depreciation & Amortization	24.18	25.39	17.75
Asset Writedown & Restructuring Costs	21.23	-	35
Loss (Gain) From Sale of Investments	-5.54	-9.46	-21.11
Stock-Based Compensation	18.04	12.43	9.54
Change in Accounts Payable	-3.81	2.95	0.24
Change in Other Net Operating Assets	81.65	77.7	9.74
Operating Cash Flow	-188.52	-134.8	-190.85
Capital Expenditures	-46.74	-84.8	-28.51
Investment in Securities	-134.6	236.15	165.46
Investing Cash Flow	-181.34	151.35	136.95
Issuance of Common Stock	1.9	0.24	0.4
Financing Cash Flow	352.05	0.24	105.81
Net Cash Flow	-17.81	16.8	51.91
Free Cash Flow	-235.26	-219.6	-219.36
Free Cash Flow Per Share	-81.29	-87.16	-108.26
Cash Interest Paid	0.89	0.03	0.04
Levered Free Cash Flow	-208.89	-190.73	-
Unlevered Free Cash Flow	-208.37	-190.71	-
Change in Working Capital	77.84	80.65	9.98

Updated Jan 9, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q